- Endocyte (ECYT) plummets as the DSMB for TARGET advises investigators and patients that vintafolide monotherapy is not likely to be declared superior in PFS to docetaxel.
- The Phase 2b trial had two arms, vintafolide monotherapy and vintafolide in combination with docetaxel, which were to be compared with standard of care (docetaxel monotherapy).
- The DSMB did recommend the continuation of the combination therapy arm.
- Top-line results are due early next year. (PR)
- ECYT -27.4% premarket
Endocyte falls as vintafolide monotherapy unlikely to show NSCLC PFS superiority
Oct 11 2013, 08:18 ET